Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Amgen and UCB, which were due to be quizzed by the European Medicines Agency in May about the investigational drug romosozumab that they are co-developing for osteoporosis, should soon find out whether their responses were good enough for the agency to recommend the medicine for pan-EU approval.
Romosozumab is among four medicines that the EMA's drug evaluation committee, CHMP, is considering for an opinion at its latest monthly meeting, which is taking place on 24-27 June. The other medicines up for an opinion are angiotensin II, lacosamide and azacitidine.
Amgen/UCB had been scheduled to attend last month's CHMP meeting to provide an "oral explanation" on the product. Oral explanations are usually organized when, at Day 180 of the drug review process, there are still major objections concerning the application that would prevent the CHMP from adopting a positive opinion on the application.
Romosozumab, a monoclonal antibody, is a novel osteoporosis treatment that increases bone formation and reduces bone resorption simultaneously to increase bone mineral density and reduce the risk of fracture. The drug is already approved for use in the US and Japan, where it is being sold under the brand name Evenity.
Regarding the other medicines that are up for a CHMP opinion this week:
Lacosamide, developed by UCB, is for the treatment of epilepsy. While UCB already holds a marketing authorization for lacosamide (Vimpat) in the EU, it told the Pink Sheet that it had submitted a new marketing authorization application (MAA) for the drug to the EMA. It said it expected that the CHMP would "decide on this MAA" during this week's meeting. According to the EMA, the agency accepted a new MAA for lacosamide in May via the informed consent application procedure (under Article 10c of Directive No 2001/83/EC), where the MA holder for the reference medicine consents to the use of its data for the application.
Azacitidine is for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia. It is not clear who the sponsor is in this case as the EMA is currently known to be reviewing four MAA applications for azacitidine, including three generics. Celgene told the Pink Sheet that it had submitted an MAA application for azacitidine in April under the informed consent application procedure, but it did not say whether this application was due for an opinion this week.
The EMA told the Pink Sheet that the CHMP assesses informed consent applications following an abridged timetable of 60 days.
The EMA will reveal the results of the CHMP's key deliberations in the meeting highlights, which are due out after the meeting ends. The CHMP's opinions are forwarded to the European Commission for the final say on marketing authorization; these legally binding decisions should be made by the commission within 67 days.
Oral Explanations For Two Orphan Drugs
In addition, sponsors of two orphan drugs were due to appear before the CHMP this week to provide oral explanations about their marketing applications. These were:
The CHMP will also examine a number of applications to extend the indications of authorized medicines. For example, applications have been made by:
Novartis Europharm regarding Revolade (eltrombopag/eltrombopag olamine) for an extension to include first line treatment of adult and paediatric patients aged two years and older with severe aplastic anaemia.
PTC Therapeutics regarding Translarna (ataluren) for an extension of indication to include non-ambulatory patients with Duchenne muscular dystrophy.
Roche for an extension of indication to include Tecentriq (atezolizumab), in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer.
Merck Sharp & Dohme for an extension of indication to include first-line treatment of advanced or metastatic renal cell carcinoma with Keytruda (pembrolizumab) and axitinib as combination therapy.
PTC Therapeutics and Novartis were due to provide an oral explanation on their respective products at the meeting.
* This article was updated on 26 June 2019 to include comments from Celgene and the EMA and to include information on PTC Therapeutics and Novartis Europharm.
In Vivo: strategic insights for life sciences decision-maker...
The COVID-19 pandemic has brought about significant manufacturing and distribution challenges and opportunities for Pharma.
Seize new opportunities and avoid risk with the strategic commercial and regulatory intelligence you need to stay competitive by subscribing to Pink Sheet and In Vivo.
Biomedtracker: see the drug development process through analysts’ eyes
Biomedtracker provides real-time analysis of major market-moving events in the pharma and biotech industries. With catalyst tracking and expert insights, Biomedtracker helps you stay on top of breaking events, the drugs pipeline, upcoming milestones, companies, and deals – and their impact on the markets you care about.